Wednesday, April 17, 2019 1:15:16 PM
Conclusions
? Human immune monitoring results support an immunologic mechanism
of action for Toca 511 & Toca FC treatment. Preliminary analyses
identified potential immune signatures that may reflect patient outcomes
and should be explored further.
• Tumor infiltrating NK cells, M0 macrophages and activated CD4+ memory T-
cells may predict patient outcomes including objective response and survival
• Peripheral serum cytokine modulations during Toca 511 & Toca FC treatment
could be useful to monitor patient responses and indicate long term survival
• Post-treatment expansion of PD-1+ and Ki-67+ T-cell subsets in the peripheral
blood of responding patients suggests potential immune activation related to
therapeutic benefit
? This clinical research helps support and clarify the immune-related
mechanism of action for Toca 511 & Toca FC previously observed in non-
clinical models
? Potential immunological associations with patient outcomes will be
evaluated in the ongoing randomized Phase 3 trial in patients with rHGG
(NCT02414165), Toca 5
https://360.aans.org/AppSearch/Eposter?eventid=48888&itemid=EPOSTER&propid=46117
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM